Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL180 in familial hypercholesterolemia
NL-OMON32563Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of APL180 in familial hypercholesterolemia (FH) and atherosclerosis (3 arms), sponsored by Novartis. Primary endpoint: Change in endothelial function. Planned start Jul 2008; status: not yet recruiting.
02
Drugs
APL180
03
Conditions
familial hypercholesterolemia (FH)atherosclerosis
Beyond the preview
Go deeper on NL-OMON32563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32563.